What is Whoop?

Whoop: subscription-only band cohort exemplar

Whoop is a subscription-only fitness + recovery biometric band. Per DEPLOY's biometric cluster framework, Whoop anchors the subscription-only band cohort exemplar within the biometric cluster: distinct commercial model from ring sub-cohort entries (RingConn subscription-free, Ultrahuman hardware+subscription, Oura purchase+membership, Happy Ring service-gated) and from Apple Watch + Garmin + Fitbit + Samsung Galaxy Watch platform-smartwatch hardware-purchase models.

---

Subscription-only commercial model: ~$478 Year 1 effective cost

Per Agent A re-verify sweep, Whoop operates the subscription-only commercial model: $239 hardware + $239/yr subscription = ~$478 Year 1 effective cost. The hardware cost is subsidized (heavily-discounted relative to band biometric peer hardware) on the requirement that subscription continues; data access requires active subscription.

Per DEPLOY's framework, the subscription-only archetype is structurally distinct from the broader biometric cluster commercial-model spectrum:

• Whoop (subscription-only): $239 hardware + $239/yr; data access requires active subscription; subsidized-hardware model.
• RingConn (subscription-free): $279 one-time purchase; all features included.
• Ultrahuman (hardware + subscription-augmented): ~$349 hardware + subscription for premium features.
• Oura (purchase + membership): hardware purchase + $5.99/mo Oura Membership for AI insights.
• Happy Ring (service-gated): NO retail price; insurer-billed Happy Sleep service bundling.

Per DEPLOY's framework, the subscription-only-band positioning makes Whoop the canonical commercial-model contrast within the biometric cluster: the only entity at the data-access-requires-subscription tier with no retail-data-access fallback.

---

$10.1B Series G March 2026 lead Collaborative Fund (CORRECTED from QIA/Mubadala)

Per Agent A re-verify sweep, Whoop closed a $10.1B Series G in March 2026 lead by Collaborative Fund. This is CORRECTED from earlier aggregator-quoted QIA/Mubadala framing which appeared in trade-press but operates outside Agent A primary-source-anchored verification of the Series G lead investor.

Per DEPLOY's framework, the funding-attribution correction matters editorially at the venture-capital-tier verification layer: trade-press coverage citing QIA/Mubadala as Series G lead operates outside Agent A primary-source-anchored verification. The Collaborative Fund lead is the load-bearing verified Series G framing. The $10.1B valuation positions Whoop at the upper venture-funded valuation tier within the consumer biometric cohort.

---

BP Insights: FDA Warning Letter dispute UNRESOLVED (May 2026)

Per Agent A re-verify sweep, Whoop's BP Insights feature operates at a manufacturer-position-vs-FDA-position editorial framing still UNRESOLVED as of May 2026:

• Manufacturer position: BP Insights "not for hypertension diagnosis" framing; positioned as lifestyle + awareness feature outside diagnostic-device scope.
• FDA position: July 14, 2025 Warning Letter to Whoop on BP Insights; FDA position is that the feature requires premarket clearance review.
• Class action: filed late 2025 / early 2026; active.
• Resolution status: UNRESOLVED as of May 2026 per Agent A re-verify confirmation.

Per cap-flag-as-trust-signal, the unresolved-dispute framing is the load-bearing verified scope; the dispute outcome operates at honest-absence posture pending FDA + class-action resolution. Per DEPLOY's framework, the manufacturer-position-vs-FDA-position editorial framing is editorial signal at the FDA-clearance verification layer within the biometric cluster.

For the within-feature editorial detail on the BP Warning Letter dispute, see the Whoop Blood Pressure Insights FDA Warning Letter feature explainer. The full-entity anchor (this explainer) surfaces the dispute as integrated commercial-model + product-features + funding-state + FDA-dispute context; the feature explainer covers the dispute at within-feature editorial depth.

---

Cohort positioning: subscription-only band cohort exemplar

Per the biometric cluster framework, Whoop anchors:

• Subscription-only band cohort exemplar: ~$478 Year 1 effective cost; data access requires active subscription; subsidized-hardware model.
• $10.1B Series G March 2026: upper venture-funded valuation tier; Collaborative Fund lead (CORRECTED from QIA/Mubadala).
• Manufacturer-position-vs-FDA-position editorial framing: BP Insights feature dispute UNRESOLVED as of May 2026; manufacturer "not for hypertension diagnosis" vs FDA July 14 2025 Warning Letter vs class action.
• Full-entity + feature-explainer integrated reference: full-entity anchor surfaces commercial + funding + dispute integrated context; BPI Warning Letter feature explainer covers dispute at within-feature editorial depth.

Contrast with cohort:

• RingConn (Gen 2 / Gen 3): subscription-free ring; AHI 90.7%-claimed but NOT FDA-cleared.
• Ultrahuman Ring (Air / Pro): hardware + subscription-augmented; market-access-redesigned.
• Happy Ring: FDA-cleared + service-gated; dual K240236 + K242224 clearances.
• Oura Ring: purchase + membership; '178 patent holder.
• Apple Watch + Garmin + Fitbit + Samsung Galaxy Watch: platform-smartwatch hardware-purchase models.

For the canonical biometric cluster context, see the biometric cluster. For the within-feature dispute detail, see Whoop Blood Pressure Insights FDA Warning Letter. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Whoop: verified-vs-claimed at within-entity granularity (CANONICAL within-Whoop sleep functions cleared vs blood-pressure Warning Letter verification scope) + the 9-tier source-quality rubric (FDA Warning Letter primary-government-record source classification).